Patent 11090261 was granted and assigned to Ocuphire Pharma, Inc. on August, 2021 by the United States Patent and Trademark Office.
The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.